High Court to hear vaccine case

The New York Times: A Supreme Court case scheduled for today will examine whether the 1986 National Childhood Vaccine Injury Act should protect manufacturers from "virtually all product liability lawsuits." The case deals with 18-year-old Hannah Bruesewitz, whose parents say she suffered developmental problems after receiving a diphtheria-tetanus-pertussis vaccine when she was six months old. That particular type of vaccine is no longer sold. The court ruling is expected to affect "hundreds of pending lawsuits that contend a link exists between childhood vaccines and autism," although the case itself is not related to autism (Meier, 10/11).

The Associated Press: "Drug companies, and the Obama administration, argue that the claims should be decided by a special vaccine court that was set up 24 years ago to insure a stable vaccine supply by shielding companies from most lawsuits" (10/12).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Late-liver-stage malaria vaccine delivers 89% protection and boosts cellular immunity